Article info

Download PDFPDF

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Authors

  1. a robert.andtbacka{at}gmail.com
  2. b Frances_collichio{at}med.unc.edu
  3. c 020 7153 5157 Kevin.Harrington{at}icr.ac.uk
  4. d mark.middleton{at}oncology.ox.ac.uk
  5. e gerald.downey{at}orchard-tx.com
  6. f kohrling{at}amgen.com
  7. g HLKaufman{at}mgh.harvard.edu
View Full Text

Citation

Andtbacka RHI, Collichio F, Harrington KJ, et al
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Publication history

  • Received December 4, 2018
  • Accepted May 17, 2019
  • First published June 6, 2019.
Online issue publication 
June 06, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.